9 Sep 2019
WCLC 2019: Phase III Fruquintinib v.s. Placebo in Advanced Non-Small Cell Lung Cancer (FALUCA)
THE LANCET :
FRESCO-2, a global Phase III study of fruquintinib in refractory metastatic colorectal cancer
Learn More
THE LANCET HAEMATOLOGY:
ESLIM-01 Phase III Study: Sovleplenib for primary immune thrombocytopenia patients in China
Learn More
THE LANCET Respiratory Medicine
Savolitinib Phase IIIb confirmatory study in treatment-naive METex14 NSCLC patients in China
Learn More
2024 Full Year Financial Results
Learn More
Latest News
20 Sep 2021HUTCHMED Initiates a Japan Bridging Study to Support Surufatinib Registration for Advanced Neuroendocrine TumorsRead more 13 Sep 2021HUTCHMED Receives Breakthrough Therapy Designation in China for Amdizalisib (HMPL-689) for Treatment of Relapsed or Refractory Follicular LymphomaRead more 8 Sep 2021HUTCHMED and AstraZeneca Initiate SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in ChinaRead more
7 Sep 2021HUTCHMED Highlights Clinical Data to be Presented at the Upcoming 2021 ESMO Virtual ConferenceRead more 6 Sep 2021HUTCHMED Announces Selection of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect ProgramsRead more 26 Aug 2021HUTCHMED Initiates a Phase Ib/II Trial of Fruquintinib in Combination with Tislelizumab in Advanced Triple Negative Breast Cancer or Advanced Endometrial CancerRead more 23 Aug 2021HUTCHMED Selected as Constituent of Certain Hang Seng IndexesRead more See all
2000
FOUNDED
HCM
NASDAQ &
LONDON AIM
LONDON AIM
13
HKEX
>20
NOVEL DRUG CANDIDATES
CREATED BY IN-HOUSE
DISCOVERY ENGINE
CREATED BY IN-HOUSE
DISCOVERY ENGINE
4
APPROVED & MARKETED
PRODUCTS IN CHINA
PRODUCTS IN CHINA
1
APPROVED & MARKETED
PRODUCT IN THE US, EU & JAPAN
PRODUCT IN THE US, EU & JAPAN
~40
CLINICAL TRIALS WORLDWIDE
INCLUDING 13+ REGISTRATION STUDIES
INCLUDING 13+ REGISTRATION STUDIES
>150,000
PATIENTS TREATED BY
OUR NOVEL MEDICINES
OUR NOVEL MEDICINES
OUR SCIENCE
Our core research and development philosophy is to take a holistic approach and treat cancer and immunological diseases through multiple modalities and mechanisms. We have taken a science-focused approach to develop highly selective, potent and well-tolerated cancer therapies that are deliberately engineered to improve drug exposure and reduce off-target toxicities.
FOLLOW HUTCHMED ON SOCIAL MEDIA
